VERU INC. Amortization of Debt Issuance Costs
VERU INC. (VERU) reported Amortization of Debt Issuance Costs of $34.30 thousand for the 12-month period ending 2021-09-30, per its 10-K filed 2022-12-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2022-12-05
- VERU INC. amortization of debt issuance costs for the quarter ending 2021-09-30 was $1.39K, a 90.78% decline year-over-year.
- VERU INC. amortization of debt issuance costs for the quarter ending 2021-06-30 was $7.70K, a 58.12% decline year-over-year.
- VERU INC. amortization of debt issuance costs for the quarter ending 2021-03-31 was $11.74K, a 40.84% decline year-over-year.
- VERU INC. amortization of debt issuance costs for the quarter ending 2020-12-31 was $13.46K, a 33.54% decline year-over-year.
- VERU INC. amortization of debt issuance costs for fiscal 2021 was $34.30K, a 53.40% decline from fiscal 2020.
- VERU INC. amortization of debt issuance costs for fiscal 2020 was $73.61K, a 23.68% decline from fiscal 2019.
- VERU INC. amortization of debt issuance costs for fiscal 2019 was $96.44K, a 54.14% increase from fiscal 2018.
- VERU INC. amortization of debt issuance costs for fiscal 2018 was $62.57K.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-09-30 | $1.39K derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-05 | $9.09K derived: sum of 2 quarters · filed 2022-12-05 | $20.84K derived: sum of 3 quarters · filed 2022-12-05 | $34.30K 10-K · filed 2022-12-05 |
| 2021-06-30 | $7.70K 10-Q · filed 2022-08-11 | $19.44K derived: sum of 2 quarters · filed 2022-08-11 | $32.91K 10-Q · filed 2022-08-11 | $48.02K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $11.74K 10-Q · filed 2022-05-12 | $25.21K 10-Q · filed 2022-05-12 | $40.32K derived: sum of 3 quarters · filed 2022-05-12 | $58.70K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $13.46K 10-Q · filed 2022-02-09 | $28.58K derived: sum of 2 quarters · filed 2022-02-09 | $46.96K derived: sum of 3 quarters · filed 2022-02-09 | $66.81K derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-09-30 | $15.11K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-02 | $33.50K derived: sum of 2 quarters · filed 2021-12-02 | $53.35K derived: sum of 3 quarters · filed 2021-12-02 | $73.61K 10-K · filed 2021-12-02 |
| 2020-06-30 | $18.39K 10-Q · filed 2021-08-12 | $38.24K derived: sum of 2 quarters · filed 2021-08-12 | $58.50K 10-Q · filed 2021-08-12 | $78.46K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $19.85K 10-Q · filed 2021-05-12 | $40.11K 10-Q · filed 2021-05-12 | $60.08K derived: sum of 3 quarters · filed 2021-05-12 | $81.98K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $20.26K 10-Q · filed 2021-02-10 | $40.23K derived: sum of 2 quarters · filed 2021-02-10 | $62.13K derived: sum of 3 quarters · filed 2021-02-10 | $88.84K derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-09-30 | $19.96K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $41.87K derived: sum of 2 quarters · filed 2020-12-10 | $68.58K derived: sum of 3 quarters · filed 2020-12-10 | $96.44K 10-K · filed 2020-12-10 |
| 2019-06-30 | $21.91K 10-Q · filed 2020-08-13 | $48.61K derived: sum of 2 quarters · filed 2020-08-13 | $76.48K 10-Q · filed 2020-08-13 | $103.28K derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $26.70K 10-Q · filed 2020-05-13 | $54.57K 10-Q · filed 2020-05-13 | $81.37K derived: sum of 3 quarters · filed 2020-05-13 | $111.57K derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $27.87K 10-Q · filed 2020-02-12 | $54.66K derived: sum of 2 quarters · filed 2020-02-12 | $84.87K derived: sum of 3 quarters · filed 2020-02-12 | $90.44K derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-09-30 | $26.80K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-12 | $57.00K derived: sum of 2 quarters · filed 2019-12-12 | $62.57K derived: sum of 3 quarters · filed 2019-12-12 | $62.57K 10-K · filed 2019-12-12 |
| 2018-06-30 | $30.20K 10-Q · filed 2019-08-08 | $35.77K derived: sum of 2 quarters · filed 2019-08-08 | $35.77K 10-Q · filed 2019-08-08 | |
| 2018-03-31 | $5.57K 10-Q · filed 2019-05-15 | $5.57K 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |